The BRINSUPRI launch trajectory is accelerating far ahead of expectations, driving a rapid path to profitability. Traders should watch for continued prescription growth data and the upcoming regulatory decision for brensocatib in Japan, which could further boost the stock. The raised peak revenue estimates to >$14B provide a long-term valuation anchor.
Price Chart
Executive Summary
Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estimates of $393.4M, driven by a 49% sequential surge in BRINSUPRI sales to $309.2M. The company raised its full-year BRINSUPRI guidance to $1.25B-$1.4B (from 'at least $1B') and boosted its peak revenue estimate for three lead programs to over $14B. The net loss narrowed dramatically to $13.2M ($0.06/share) from $321.7M ($1.70/share) a year ago, signaling a rapid path to profitability.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $425.5M, up 296% YoY vs $107.4M.
- BRINSUPRI revenue of $309.2M, up 49% sequentially from Q1 2026.
- Full-year 2026 BRINSUPRI guidance raised to $1.25B-$1.40B from 'at least $1B'.
- Peak revenue estimate raised to >$14B combined for BRINSUPRI, TPIP, and ARIKAYCE.
- Net loss narrowed to $13.2M ($0.06/share) from $321.7M ($1.70/share) in Q2 2025.
- Cash, cash equivalents, and marketable securities of ~$1.2B as of June 30, 2026.
- sNDA submitted to FDA in July for ARIKAYCE label expansion to newly diagnosed MAC lung disease patients.
- Positive 12-month OLE data for TPIP in PAH reported in July 2026.
Financial Impact
Revenue beat consensus by $32.1M (+8.2%); EPS of -$0.06 was a massive beat vs consensus of -$0.68; BRINSUPRI guidance raised by $250M-$400M at the midpoint.
Risk Factors
- Execution risk in sustaining BRINSUPRI's rapid launch trajectory.
- Regulatory risk for ARIKAYCE label expansion and brensocatib approval in Japan.
- High R&D and SG&A spending as the company invests in pipeline and commercial infrastructure.
- Dependence on a single product (BRINSUPRI) for near-term growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-031502 |
| Document: ef20079469_ex99-2.htm | 0001140361-26-031502 |
| Document: ef20079469_8k.htm | 0001140361-26-031502 |
| Document: 0001140361-26-031502-index-headers.html | 0001140361-26-031502 |
| Document: 0001140361-26-031502-index.html | 0001140361-26-031502 |
| Document: 0001140361-26-031502.txt | 0001140361-26-031502 |
| 8-K Data (Synthetic) | 0001140361-26-031502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $130.66 $119.92 | ▼ −8.22% | ▼ −6.70% | $109.99 (−15.82%) |
Aug 12, 2026 7w ago | Insider Cluster | $126.33 $129.41 | ▲ +2.44% | ▲ +4.19% | $109.99 (−12.93%) |
Aug 6, 2026 8w ago | 8-K | $132.55 $126.68 | ▼ −4.43% | ▼ −5.03% | $109.99 (−17.02%) |
Jul 24, 2026 10w ago | Institutional Cluster | $106.92 $125.77 | ▲ +17.63% | ▲ +14.00% | $109.99 (+2.87%) |
Jul 21, 2026 10w ago | ANALYST-UPGRADE | $108.62 $128.46 | ▲ +18.27% | ▲ +15.70% | $109.99 (+1.26%) |
Jul 16, 2026 11w ago | 8-K | $107.46 $126.33 | ▲ +17.56% | ▲ +13.94% | $109.99 (+2.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $104.74 $106.92 | ▲ +2.08% | ▲ +2.36% | $109.99 (+5.01%) |
Jun 5, 2026 16w ago | Insider Cluster | $94.17 $111.54 | ▲ +18.45% | ▲ +16.81% | $109.99 (+16.80%) |
Jun 5, 2026 16w ago | Insider Cluster | $94.17 $111.54 | ▲ +18.45% | ▲ +16.81% | $109.99 (+16.80%) |
May 15, 2026 19w ago | S-3ASR | $107.15 $95.52 | ▼ −10.85% | ▼ −12.44% | $109.99 (+2.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access